Literature DB >> 24793164

Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension.

Kazuyo Yamaji-Kegan1, Eiki Takimoto2, Ailan Zhang3, Noah C Weiner3, Lucas W Meuchel3, Alan E Berger4, Chris Cheadle4, Roger A Johns3.   

Abstract

Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure that leads to progressive right heart failure and ultimately death. Injury to endothelium and consequent wound repair cascades have been suggested to trigger pulmonary vascular remodeling, such as that observed during PH. The relationship between injury to endothelium and disease pathogenesis in this disorder remains poorly understood. We and others have shown that, in mice, hypoxia-induced mitogenic factor (HIMF, also known as FIZZ1 or RELMα) plays a critical role in the pathogenesis of lung inflammation and the development of PH. In this study, we dissected the mechanism by which HIMF and its human homolog resistin (hRETN) induce pulmonary endothelial cell (EC) apoptosis and subsequent lung inflammation-mediated PH, which exhibits many of the hallmarks of the human disease. Systemic administration of HIMF caused increases in EC apoptosis and interleukin (IL)-4-dependent vascular inflammatory marker expression in mouse lung during the early inflammation phase. In vitro, HIMF, hRETN, and IL-4 activated pulmonary microvascular ECs (PMVECs) by increasing angiopoietin-2 expression and induced PMVEC apoptosis. In addition, the conditioned medium from hRETN-treated ECs had elevated levels of endothelin-1 and caused significant increases in pulmonary vascular smooth muscle cell proliferation. Last, HIMF treatment caused development of PH that was characterized by pulmonary vascular remodeling and right heart failure in wild-type mice but not in IL-4 knockout mice. These data suggest that HIMF contributes to activation of vascular inflammation at least in part by inducing EC apoptosis in the lung. These events lead to subsequent PH.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  T-helper type 2 inflammation; endothelial apoptosis; human resistin

Mesh:

Substances:

Year:  2014        PMID: 24793164      PMCID: PMC4060011          DOI: 10.1152/ajplung.00279.2013

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  63 in total

1.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

2.  Contribution of alternatively activated macrophages to allergic lung inflammation: a tale of mice and men.

Authors:  Preeta Dasgupta; Achsah D Keegan
Journal:  J Innate Immun       Date:  2012-03-21       Impact factor: 7.349

3.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

4.  Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats.

Authors:  Elie R Chemaly; Lahouaria Hadri; Shihong Zhang; Maengjo Kim; Erik Kohlbrenner; Jipo Sheng; Lifan Liang; Jiqiu Chen; Purushothaman K-Raman; Roger J Hajjar; Djamel Lebeche
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

Review 5.  The stress-activated protein kinase pathways.

Authors:  L A Tibbles; J R Woodgett
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

6.  Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension.

Authors:  Daniel J Angelini; Qingning Su; Kazuyo Yamaji-Kegan; Chunling Fan; Xingwu Teng; Paul M Hassoun; Stephen C Yang; Hunter C Champion; Rubin M Tuder; Roger A Johns
Journal:  Am J Respir Cell Mol Biol       Date:  2009-02-27       Impact factor: 6.914

7.  Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme.

Authors:  Y J Geng; P Libby
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

8.  Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.

Authors:  Hee Sun Koo; Kwan Chang Kim; Young Mi Hong
Journal:  Korean Circ J       Date:  2011-02-28       Impact factor: 3.243

9.  The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.

Authors:  Lakshmi Kugathasan; Julie Basu Ray; Yupu Deng; Effat Rezaei; Daniel J Dumont; Duncan J Stewart
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

10.  Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling.

Authors:  Daniel J Angelini; Qingning Su; Kazuyo Yamaji-Kegan; Chunling Fan; John T Skinner; Andre Poloczek; Hazim El-Haddad; Chris Cheadle; Roger A Johns
Journal:  Respir Res       Date:  2013-01-04
View more
  32 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

3.  Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia.

Authors:  Maria Haslip; Iva Dostanic; Yan Huang; Yi Zhang; Kerry S Russell; Michael J Jurczak; Praveen Mannam; Frank Giordano; Serpil C Erzurum; Patty J Lee
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-26       Impact factor: 8.311

4.  Iptakalim ameliorates hypoxia-impaired human endothelial colony-forming cells proliferation, migration, and angiogenesis via Akt/eNOS pathways.

Authors:  Mengyu He; Ting Cui; Qing Cai; Hong Wang; Hui Kong; Weiping Xie
Journal:  Pulm Circ       Date:  2019-10-18       Impact factor: 3.017

5.  RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.

Authors:  Qing Lin; Chunling Fan; John T Skinner; Elizabeth N Hunter; Andrew A Macdonald; Peter B Illei; Kazuyo Yamaji-Kegan; Roger A Johns
Journal:  J Immunol       Date:  2019-10-14       Impact factor: 5.422

6.  Biomarkers of hypoxia, endothelial and circulatory dysfunction among climbers in Nepal with AMS and HAPE: a prospective case-control study.

Authors:  Kevin R Barker; Andrea L Conroy; Michael Hawkes; Holly Murphy; Prativa Pandey; Kevin C Kain
Journal:  J Travel Med       Date:  2016-03-16       Impact factor: 8.490

Review 7.  Interleukin 4: Its Role in Hypertension, Atherosclerosis, Valvular, and Nonvalvular Cardiovascular Diseases.

Authors:  Kamal M Kassem; Mahboob Ali; Nour-Eddine Rhaleb
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-08-11       Impact factor: 2.457

Review 8.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

9.  RELMα can cause contraction of rat aortic smooth muscle cells.

Authors:  Xiaoyan Li; Shuxiang Duan; Hongming Zhang; Shufang Han; Qun Jin; Rui Cui
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  Resistin family proteins in pulmonary diseases.

Authors:  Qing Lin; Roger A Johns
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-06-17       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.